Stepwise evolution of therapy resistance in AML
Author:
Funder
National Institutes of Health
Publisher
Elsevier BV
Subject
Cancer Research,Cell Biology,Oncology
Reference10 articles.
1. Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date;Fletcher;Cancer Manag. Res.,2020
2. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition;Hangauer;Nature,2017
3. The AML microenvironment catalyzes a step-wise evolution to gilteritinib resistance;Joshi;Cancer Cell,2021
4. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches;Konopleva;Drug Resist. Updat.,2009
5. New agents: great expectations not realized;Lancet;Best Pract. Res. Clin. Haematol.,2013
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Key role of glutamine metabolism in persistence of leukemic cells upon exposition to FLT3 tyrosine kinase inhibitors;Experimental Hematology;2024-09
2. Glucose Metabolism as a Potential Therapeutic Target in Cytarabine-Resistant Acute Myeloid Leukemia;Pharmaceutics;2024-03-22
3. Tegaserod maleate exhibits antileukemic activity by targeting TRPM8;Biomedicine & Pharmacotherapy;2022-10
4. Explainable artificial intelligence for precision medicine in acute myeloid leukemia;Frontiers in Immunology;2022-09-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3